Cover Image
市場調查報告書

胃接處腺癌:開發中產品分析

Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 257785
出版日期 內容資訊 英文 320 Pages
訂單完成後即時交付
價格
Back to Top
胃接處腺癌:開發中產品分析 Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016
出版日期: 2016年11月23日 內容資訊: 英文 320 Pages
簡介

所謂胃食道接合處腺癌是食道和胃食道結點的癌症。症候有失語症,體重減少,咳嗽,吞嚥疼痛,疼痛,聲音嘶啞等。因素有高齡化,體重過重(肥胖),胃食道逆流(GERD),抽煙,酒精中毒。治療方法有化療和放射線治療。

本報告提供胃接處腺癌的治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,再加上企業和研究機關開發中的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

胃接處腺癌概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

胃接處腺癌:企業開發中的治療藥

胃接處腺癌:大學/機關研究中的治療藥

胃接處腺癌:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

胃接處腺癌:企業開發中的產品

胃接處腺癌:大學/機關研究中的產品

胃接處腺癌的治療藥的開發企業

  • AB Science SA
  • AbbVie Inc.
  • Advenchen Laboratories, LLC
  • Amgen Inc.
  • ArQule, Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Boston Biomedical, Inc.
  • Bristol-Myers Squibb Company
  • Cerulean Pharma, Inc.
  • 第一三共
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Ganymed Pharmaceuticals AG
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • Imugene Limited
  • Johnson & Johnson
  • Mebiopharm Co., Ltd.
  • MedImmune, LLC
  • Merck & Co., Inc.
  • Merck KGaA
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Oncobiologics, Inc.
  • Panacea Biotec Limited
  • Sanofi
  • 大鵬藥品工業

胃接處腺癌:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

胃接處腺癌:最近的開發平台趨勢

胃接處腺癌:暫停中的計劃

胃接處腺癌:開發中止的產品

胃接處腺癌:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8688IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides an overview of the Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline landscape.

Gastroesophageal (GE) junction adenocarcinomas are carcinomas of the esophagus and the gastro-esophageal junction. Symptoms include dysphasia, weight loss, cough, odynophagia, pain and hoarseness. Risk factors include age, overweight or obese, gastroesophageal reflux disease (GERD), smoking and alcoholism. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adenocarcinoma Of The Gastroesophageal Junction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 8, 23, 10 and 5 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.Adenocarcinoma Of The Gastroesophageal Junction.

Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adenocarcinoma Of The Gastroesophageal Junction (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adenocarcinoma Of The Gastroesophageal Junction (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adenocarcinoma Of The Gastroesophageal Junction (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adenocarcinoma Of The Gastroesophageal Junction (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Adenocarcinoma Of The Gastroesophageal Junction Overview
  • Therapeutics Development
    • Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Overview
    • Pipeline Products for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Development by Companies
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics under Investigation by Universities/Institutes
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Adenocarcinoma Of The Gastroesophageal Junction - Products under Development by Companies
  • Adenocarcinoma Of The Gastroesophageal Junction - Products under Investigation by Universities/Institutes
  • Adenocarcinoma Of The Gastroesophageal Junction - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc
    • Advenchen Laboratories, LLC
    • Amgen Inc.
    • ArQule, Inc.
    • AstraZeneca Plc
    • Boehringer Ingelheim GmbH
    • Boston Biomedical, Inc.
    • Bristol-Myers Squibb Company
    • Cerulean Pharma, Inc.
    • Daiichi Sankyo Company, Limited
    • Dr. Reddy's Laboratories Limited
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Ganymed Pharmaceuticals AG
    • Genentech Inc
    • Gilead Sciences, Inc.
    • Hutchison MediPharma Limited
    • Imugene Limited
    • Mebiopharm Co., Ltd.
    • MedImmune LLC
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Neopharm Ltd.
    • Novartis AG
    • Oncobiologics, Inc.
    • Panacea Biotec Limited
    • Sanofi
  • Adenocarcinoma Of The Gastroesophageal Junction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AL-3818 - Drug Profile
    • alpelisib - Drug Profile
    • AMG-337 - Drug Profile
    • atezolizumab - Drug Profile
    • avelumab - Drug Profile
    • AZD-4547 - Drug Profile
    • AZD-6738 - Drug Profile
    • BI-853520 - Drug Profile
    • cabazitaxel - Drug Profile
    • catumaxomab - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • ceritinib - Drug Profile
    • CRLX-101 - Drug Profile
    • DS-8201 - Drug Profile
    • durvalumab - Drug Profile
    • durvalumab + tremelimumab - Drug Profile
    • emibetuzumab - Drug Profile
    • GS-5745 - Drug Profile
    • ibrutinib - Drug Profile
    • IMAB-362 - Drug Profile
    • IMU-131 - Drug Profile
    • ipatasertib - Drug Profile
    • ipilimumab - Drug Profile
    • JS-001 - Drug Profile
    • LAG-525 - Drug Profile
    • LY-3127804 - Drug Profile
    • masitinib - Drug Profile
    • merestinib - Drug Profile
    • napabucasin - Drug Profile
    • nimotuzumab - Drug Profile
    • oxaliplatin - Drug Profile
    • panitumumab - Drug Profile
    • PDR-001 - Drug Profile
    • pembrolizumab - Drug Profile
    • pertuzumab - Drug Profile
    • ramucirumab - Drug Profile
    • SAR-408701 - Drug Profile
    • savolitinib - Drug Profile
    • serabelisib - Drug Profile
    • sonidegib phosphate - Drug Profile
    • tivantinib - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • trastuzumab biosimilar - Drug Profile
    • tremelimumab - Drug Profile
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects
  • Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products
  • Adenocarcinoma Of The Gastroesophageal Junction - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016
  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AB Science SA, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AbbVie Inc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Amgen Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by ArQule, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by AstraZeneca Plc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Boston Biomedical, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Eli Lilly and Company, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Genentech Inc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Gilead Sciences, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Hutchison MediPharma Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Imugene Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Mebiopharm Co., Ltd., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by MedImmune LLC, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck & Co., Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Merck KGaA, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Neopharm Ltd., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Novartis AG, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Oncobiologics, Inc., H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Panacea Biotec Limited, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Pipeline by Sanofi, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects, H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Dormant Projects (Contd..1), H2 2016
  • Adenocarcinoma Of The Gastroesophageal Junction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction, H2 2016
  • Number of Products under Development for Adenocarcinoma Of The Gastroesophageal Junction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top